Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | CTSD | P07339 | 4/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.33 |
| ▸ | SDCBP | O00560 | 1/20 | 0.33 |
| ▸ | SDC2 | P34741 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4968369 | 0.91 | NPSR1 (0.43) | NPSR1MMESMN1; SMN2ALDH1A1POLB | |
| SCHEMBL4968366 | 0.91 | NPSR1 (0.43) | NPSR1MMESMN1; SMN2ALDH1A1POLB | |
| SCHEMBL29531660 | 0.91 | NPSR1 (0.43) | NPSR1MMESMN1; SMN2ALDH1A1POLB | |
| SCHEMBL30997444 | 0.89 | NPSR1 (0.42) | NPSR1MMESMN1; SMN2ALDH1A1POLB | |
| SCHEMBL29839283 | 0.86 | NPSR1 (0.40) | NPSR1CTSDMMESMN1; SMN2ALDH1A1 | |
| SCHEMBL31265320 | 0.84 | NPSR1 (0.38) | NPSR1CTSDMMESMN1; SMN2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL7435083 | 0.83 | ITGB1 (0.40) | NPSR1CTSDCTSC | |
| SCHEMBL31631407 | 0.80 | MME (0.39) | CTSDMMESMN1; SMN2ALDH1A1CTSC | |
| SCHEMBL29380611 | 0.79 | NPSR1 (0.47) | NPSR1CTSDMMESMN1; SMN2ALDH1A1 | |
| SCHEMBL232334 | 0.79 | NPSR1 (0.53) | NPSR1SMN1; SMN2ALDH1A1CTSCPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120308646-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ZHANG HESHENG (CN) | 2012-12-06 | — | — | US | disclosed |
| US-20090325894-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ZHANG HESHENG | 2009-12-31 | — | — | US | disclosed |
| EP-2123283-A1 | THE TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER EFFECT | Tianjin Hemey Bio-Tech Co., Ltd. (CN) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325894-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | GLS2, GLS, VIP | NPSR1 3134/4885CTSD 3616/4885MME 4617/4885 |
| US-20120308646-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ALAD, SLC27A2, ANTXR2 | NPSR1 3774/4885CTSD 2661/4885MME 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.